Charité is among the largest university hospitals in Europe, with 13,200 employees and more than 100 clinics and institutes within 17 CharitéCenters at its four campuses. PPD will collaborate with the CTMU to shorten study start-up times, maximize the number of patients recruited for trials, generate high-quality data, and ensure all site staff members are properly trained for the conduct of clinical studies. The agreement includes a range of Phase I-IV trials across multiple therapeutic areas.
“Germany’s abundance of intellectual and technical resources, coupled with the ongoing advances that have streamlined the clinical research process, make the country extremely attractive for clinical research,” said Roger Newbery, PPD’s vice president of clinical management for Europe, Middle East and Africa. “We welcome the opportunity to strengthen our relationship with a world-class treatment facility that is one of our most experienced and most frequently used clinical research sites globally. Likewise, we are pleased to enhance our support for our clients in expanding their research programs in Germany and around the world.”
“By extending our relationship with PPD, our aim is to ensure improved access to novel medicines and advance our mission of securing lasting health improvements for our patients,” said Gerrit Fleige, executive director, finance and administration of the medical faculty of the Charité–Universitätsmedizin Berlin. “As one of the world’s leading CROs, PPD is able to provide us with a wealth of capabilities and services."